查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1929524

全球淀粉样蛋白抗治疗市场（依治疗类型、适应症、给药途径、作用机制、患者年龄层和最终用户划分）预测（2026-2032年）

Anti-amyloid Therapy Market by Therapy Type, Indication, Route Of Administration, Mechanism Of Action, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗淀粉样蛋白治疗市场规模将达到 73.9 亿美元，到 2026 年将成长至 79.9 亿美元，复合年增长率为 13.92%，到 2032 年将达到 184.2 亿美元。

关键市场统计数据
基准年 2025 73.9亿美元
预计年份：2026年 79.9亿美元
预测年份 2032 184.2亿美元
复合年增长率 (%) 13.92%

目前抗淀粉样蛋白治疗环境的框架，其中科学进步、监管变化和支付方决策共同决定临床和商业性结果。

抗淀粉样蛋白治疗领域已进入关键阶段，科学检验、监管政策的重新解读以及支付者的决策正在交汇融合，重塑临床路径和商业策略。生物製药的进步正在拓展治疗工具箱，而不断发展的诊断能力和患者识别策略正在优化缓解疾病干预的目标族群。同时，包括研究机构、生命科学公司、医疗保健系统和支付方在内的相关人员正在重新调整工作重点，以平衡临床效益、安全性以及长期价值创造。

科学进步、监管调整和支付方框架的演变如何共同重塑临床开发、商业化和病患就医途径？

近期科学突破、监管机构的讯号以及支付方的实验性措施正在共同推动抗淀粉样蛋白疗法领域的变革。免疫疗法和标靶胜肽疗法已从概念验证迈向更广泛的临床应用，迫使监管机构重新评估证据要件和有条件核准途径。儘管这些政策调整降低了部分市场进入门槛，但也加强了对真实世界疗效和安全性监测的审查，并迫使申办方设计超越随机对照试验的综合证据产生策略。

评估2025年美国关税将如何重塑抗淀粉样蛋白治疗生态系统的供应链韧性、製造经济和支付方动态。

2025年美国关税将改变全球药品供应链的经济和物流结构，进而为抗淀粉样蛋白治疗领域的相关人员带来更多挑战。这些关税将增加活性药物原料药、生物製药製剂原料、特殊试剂以及某些成品在国际生产网络中的成本，促使製造商重新评估其筹资策略和库存管理政策。为此，许多机构正在加速供应商多元化、投资近岸生产以及建立策略性库存缓衝机制，以降低关税波动带来的风险，并确保临床试验用药和商业分销的持续供应。

基于深度细分的洞察，揭示了治疗层级、适应症、给药途径、医疗环境、分销管道、作用机制和年龄层的策略影响

观点市场进行细分，可以揭示相关人员可以利用的、实现临床和商业性差异化的微妙路径。依治疗方法类型划分，竞争格局包括单株抗体、胜肽和小分子药物，其中单株抗体可进一步细分为嵌合体、全人源型和人源化型。每类药物都有其独特的生产需求、免疫抗原性特征和监管预期，这些都会影响研发进度和商业化策略。依适应症划分，轻度至中度阿兹海默症和重度阿兹海默症的临床策略有所不同，其中轻度至中度阿兹海默症可进一步细分为轻度和中度。这些适应症的细微差别决定了试验终点、病患入组标准和核准后证据要求。

美洲、欧洲、中东和非洲以及亚太地区的区域战略重点将影响监管方式、准入途径和商业化策略。

区域趋势将对监管路径、报销环境和商业部署策略产生决定性影响，对美洲、欧洲、中东和非洲以及亚太地区的影响各不相同。在美洲，监管先例和支付方谈判机制往往倾向于强有力的证据包和基于价值的合约试点项目，促使製造商与主要医疗系统合作，投资于真实世界证据和分阶段部​​署策略。同时，该地区部分地区先进的诊断基础设施正在加速患者识别，但仍存在就医难的问题，需要补充患者外展服务和中心辐射式分销模式来覆盖都市区。

生物製药创新者、生物技术新创参与企业、合约研发生产机构 (CDMO) 和诊断合作伙伴之间的竞争与合作策略，塑造了产品差异化和商业成功。

活跃于抗淀粉样蛋白领域的主要企业透过专业化的研发管线、策略合作以及对上游诊断和下游患者支持的投资来实现差异化。大型生物製药公司专注于抗体工程和可扩展生技药品生产的平台能力，而规模较小的生物技术公司则往往致力于开发独特的作用机制和创新的递送平台，以创造差异化的临床价值。合约研发生产机构（CDMO）在实现复杂生技药品和胜肽类药物的可扩展生产方面发挥着至关重要的作用，其产能限制和扩张对申办方的策略和上市时间有着重大影响。

为领导者提供切实可行的策略建议，以协调研发、生产韧性、诊断伙伴关係、定价创新和以病人为中心的医疗服务取得计画。

产业领导者应协调一致地采取一系列策略行动，以在抗淀粉样蛋白领域获得临床、监管和商业性优势。首先，为使研发计画与下游证据要求保持一致，应将真实世界资料收集和病患报告结果纳入临床实验和核准后监测，同时解决监管机构和支付方提出的问题。其次，应实现生产和采购基地多元化，以降低地缘政治风险和关税干扰的影响。考虑将关键零件的生产外包到附近地区，并协商灵活的供应商协议，以确保供应的连续性。第三，应投资于诊断伙伴关係和临床医生培训，以加速准确识别患者和合理用药，这将有助于与支付者沟通并推动药物的普及应用。

为确保研究结果可靠且可操作，我们采用了稳健的混合调查方法，结合了相关人员访谈、二手证据综合、三角验证和检验。

本研究采用混合方法，结合质性相关人员观点和系统性证据综合，以获得严谨且可操作的见解。主要研究包括对临床研究人员、医疗系统领导者、监管事务专业人员、支付方代表和生产专家进行深度访谈，以收集关于临床终点、试验可行性、报销考量和供应链限制的第一手资讯。为补充这些访谈，次要证据综合分析了同行评审文献、监管指导文件、临床试验註册库和公司披露信息，以梳理科学进展、安全性考虑和监管态度。

综合结论强调了在将抗淀粉样蛋白治疗创新转化为持续的患者可及性方面取得的进展、面临的多重挑战以及所需的策略重点。

总之，抗淀粉样蛋白治疗领域兼具科学前景与系统复杂性，需要整合实证策略。单株抗体、胜肽和小分子药物等治疗创新为影响疾病生物学提供了多种途径，但每种方法都面临独特的生产、临床和医疗保险报销挑战。法规环境和支付环境也在同步发展，对真实世界证据和可验证的功能性结果的要求日益提高，因此，积极主动地制定核准后研究计划和创造性的合约模式至关重要。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 淀粉样蛋白抗疗法市场（依治疗方法）

  • 单株抗体
    • 嵌合体单株抗体
    • 完全人体单株抗体
    • 人源化单株抗体
  • 胜肽
  • 低分子化合物

9. 依适应症分類的淀粉样蛋白抗治疗市场

  • 轻度至中度阿兹海默症
    • 轻度阿兹海默症
    • 中度阿兹海默症
  • 重度阿兹海默症

10. 依给药途径分類的淀粉样蛋白抗治疗市场

  • 静脉注射
  • 口服
  • 皮下注射

11. 依作用机转分類的淀粉样蛋白抗治疗市场

  • 抑制β-淀粉样蛋白聚集
  • β-淀粉样蛋白清除
  • 抑制β-淀粉样蛋白的产生
  • 神经炎症调节

12. 依患者年龄层分類的淀粉样蛋白抗治疗市场

  • 65-74岁
  • 75岁或以上
  • 65岁以下

13. 依最终用户分類的淀粉样蛋白抗治疗市场

  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院
  • 专科诊所
  • 远端医疗服务

14. 各地区淀粉样蛋白抗疗法市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 淀粉样蛋白抗疗法市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国淀粉样蛋白抗疗法市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国淀粉样蛋白抗疗法市场

第十八章：中国的淀粉样蛋白抗治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A38069517F4

The Anti-amyloid Therapy Market was valued at USD 7.39 billion in 2025 and is projected to grow to USD 7.99 billion in 2026, with a CAGR of 13.92%, reaching USD 18.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.39 billion
Estimated Year [2026] USD 7.99 billion
Forecast Year [2032] USD 18.42 billion
CAGR (%) 13.92%

Framing the current anti-amyloid therapeutic environment where scientific advances, regulatory shifts, and payer decisions jointly determine clinical and commercial outcomes

The anti-amyloid therapeutic space has entered a decisive phase, where scientific validation, regulatory reinterpretation, and payer adjudication converge to reshape clinical trajectories and commercial strategies. Advances in biologics, peptide chemistry, and small-molecule approaches have expanded the therapeutic toolkit, while evolving diagnostic capabilities and patient identification strategies refine the target population for disease-modifying interventions. Concurrently, stakeholders across research institutions, life sciences companies, health systems, and payers are recalibrating priorities to balance clinical benefit, safety profiles, and long-term value generation.

This introduction positions the reader to appreciate how technological innovation intersects with regulatory precedent and payer behavior to influence adoption curves, clinical pathways, and supply chain design. It underscores the urgency for cross-functional alignment: clinical development teams must coordinate with manufacturing and market access stakeholders to translate laboratory advances into accessible therapies. By framing the current environment in terms of scientific momentum and systemic friction points, the following sections illuminate where strategic interventions can materially affect outcomes for patients and organizations alike.

How scientific advances, regulatory recalibration, and evolving payer frameworks are jointly redefining clinical development, commercialization, and patient access

Recent scientific breakthroughs, regulatory signals, and payer experiments are collectively producing transformative shifts across the anti-amyloid therapy landscape. Immunotherapies and targeted peptides have progressed from proof-of-concept into broader clinical application, prompting regulators to refine evidentiary expectations and conditional pathways. These policy adaptations have lowered certain barriers to market entry but also heightened scrutiny on real-world effectiveness and safety monitoring, prompting sponsors to design integrated evidence generation strategies that extend beyond randomized controlled trials.

At the same time, payers and health technology assessors are experimenting with outcome-based reimbursement models and coverage with evidence development, which reshapes commercial planning and patient access strategies. Manufacturers must therefore craft value dossiers that demonstrate not only biomarker modulation but meaningful cognitive and functional outcomes across clinically relevant time horizons. Moreover, diagnostic advancement, particularly in imaging and fluid biomarkers, is changing referral patterns and enabling earlier intervention, which in turn impacts trial design, patient recruitment, and long-term care models. Taken together, these shifts demand agile clinical programs, adaptive regulatory engagement, and proactive payer dialogue to secure sustainable adoption of anti-amyloid therapeutics.

Assessing how 2025 United States tariff measures could reshape supply chain resiliency, manufacturing economics, and payer dynamics across the anti-amyloid therapy ecosystem

United States tariff actions in 2025 introduce another layer of complexity for anti-amyloid therapy stakeholders by altering the economics and logistics of global pharmaceutical supply chains. Tariffs can increase costs for active pharmaceutical ingredients, biologics components, specialized reagents, and certain finished products that traverse international manufacturing networks, prompting manufacturers to reassess sourcing strategies and inventory policies. In response, many organizations will accelerate supplier diversification, nearshore manufacturing investments, and strategic inventory buffering to mitigate exposure to tariff volatility and to sustain uninterrupted clinical trial supply and commercial distribution.

Tariff-driven cost pressures also have implications for contract manufacturing organizations and service providers that support biologics and peptide synthesis, potentially compressing margins and forcing repricing negotiations. Payers and hospital procurement teams may face higher acquisition costs for therapies, which could influence formulary decisions and prior authorization requirements. From a research perspective, increased import costs for specialized lab materials could slow some discovery programs or shift early-stage work toward domestic hubs and academic partnerships. Overall, tariffs amplify the need for scenario planning, contract flexibility, and enhanced coordination across procurement, regulatory, and commercial teams to preserve access and maintain investment in long-term clinical programs.

Deep segmentation-driven insights revealing how therapy classes, indications, administration routes, care settings, distribution channels, mechanisms, and age cohorts influence strategy

Disaggregating the market through distinct segmentation lenses reveals nuanced pathways to clinical and commercial differentiation that stakeholders can exploit. Based on therapy type, the competitive field includes monoclonal antibodies, peptides, and small molecules, with monoclonal antibodies further differentiated into chimeric, fully human, and humanized constructs; each class carries unique manufacturing demands, immunogenicity profiles, and regulatory expectations that influence development timelines and commercialization strategies. Based on indication, clinical strategy varies between Alzheimer's disease mild-to-moderate and Alzheimer's disease severe, with the mild-to-moderate category further subdivided into mild and moderate disease states; these indication nuances determine trial endpoints, patient selection criteria, and post-approval evidence commitments.

Based on route of administration, delivery modality analysis must consider intravenous, oral, and subcutaneous options, because administration route affects patient adherence, site-of-care economics, and cold-chain requirements. Based on end user, utilization patterns differ across home care, hospitals, specialty clinics, and telehealth services, with hospitals further distinguished as private and public institutions; these distinctions matter for distribution logistics, payer negotiations, and real-world monitoring. Based on distribution channel, the pathways include direct-to-patient distribution, hospital pharmacies, online pharmacies, and retail pharmacies, and hospital pharmacies can be divided into inpatient and outpatient settings; channel selection impacts patient access, reimbursement flow, and patient support program design. Based on mechanism of action, therapeutic strategies range from beta amyloid aggregation inhibition, beta amyloid clearance, beta amyloid production reduction, to neuroinflammation modulation, and each mechanism implies different biomarker strategies and safety surveillance needs. Finally, based on patient age group, clinical and commercial approaches must address cohorts of 65 to 74 years, 75 years and above, and below 65 years, since age stratification influences risk profile, comorbidity management, and health-system engagement. Synthesizing these segmentation lenses enables stakeholders to prioritize investments in development pathways, manufacturing capacity, diagnostic partnerships, and patient support infrastructures that align with targeted clinical benefits and payer expectations.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine regulatory approach, access pathways, and commercialization tactics

Regional dynamics exert a decisive influence on regulatory pathways, reimbursement environments, and commercial roll-out strategies, with distinct implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory precedent and payer negotiation mechanisms tend to favor robust evidence packages and value-based contracting pilots, which drives manufacturers to invest in real-world evidence and phased rollout strategies aligned with major health systems. Meanwhile, infrastructure for advanced diagnostics in some parts of the region accelerates patient identification, but access disparities require complementary patient support and hub-and-spoke distribution models to reach non-urban populations.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement frameworks demand localized market access strategies, partnerships with regional distributors, and adaptive pricing approaches. Several jurisdictions emphasize health technology assessments and long-term outcome data, which incentivizes manufacturers to build registries and conditional reimbursement arrangements. In the Asia-Pacific region, growing investment in biotech manufacturing capacity and expanding diagnostic capabilities create opportunities for rapid clinical scale-up, but stakeholders must navigate variable regulatory timelines, local clinical practice patterns, and diverse payer landscapes. Across all regions, strategic collaboration with local clinical champions, payers, and diagnostics providers expedites adoption while mitigating geopolitical and tariff-induced supply risks.

Competitive and partnership strategies among biopharma innovators, biotechnology entrants, CDMOs, and diagnostics partners that shape product differentiation and commercialization success

Key companies operating in the anti-amyloid domain are differentiating through specialized pipelines, strategic collaborations, and investments in upstream diagnostics and downstream patient support. Biopharmaceutical leaders focus on platform capabilities in antibody engineering and scalable biologics manufacturing, while smaller biotechnology firms often pursue niche mechanisms of action or innovative delivery platforms to carve differentiated clinical value. Contract development and manufacturing organizations play a pivotal role in enabling scalable production for complex biologics and peptides, and their capacity constraints or expansions materially affect sponsor strategy and launch timing.

Strategic partnerships between therapeutic developers and diagnostic companies are increasingly central, as reliable biomarker-driven patient identification underpins payer acceptance and efficient clinical trial enrollment. Additionally, alliances with specialty pharmacies and in-home care providers reinforce continuity of care and adherence, especially for therapies requiring ongoing administration or monitoring. Payer engagement strategies vary by company, from early HTA dialogues to pilot outcomes agreements, and successful organizations pair clinical evidence generation with pragmatic reimbursement pilots to demonstrate value in routine care. Collectively, these corporate strategies reflect a broader industry trend toward integrated, evidence-informed commercialization that aligns R&D investment with downstream access imperatives.

Actionable strategic recommendations for leaders to align R&D, manufacturing resilience, diagnostic partnerships, pricing innovation, and patient-centric access programs

Industry leaders should adopt a coordinated set of strategic actions to capture clinical, regulatory, and commercial advantage in the anti-amyloid space. First, align development programs with downstream evidence needs by integrating real-world data collection and patient-reported outcomes into pivotal and post-approval studies to address regulator and payer questions concurrently. Second, diversify manufacturing and procurement footprints to reduce exposure to geopolitical and tariff disruptions; consider nearshoring critical components and negotiating flexible supplier agreements to maintain supply continuity. Third, invest in diagnostic partnerships and clinician education to accelerate accurate patient identification and appropriate use, which will support payer discussions and enhance uptake.

Fourth, design flexible pricing and reimbursement strategies, including outcome-based arrangements and staged access models, to share risk with payers while building a robust evidentiary base. Fifth, develop patient-centric delivery and support programs that optimize adherence, monitor safety, and reduce treatment abandonment-these programs should integrate telehealth touchpoints and home-based services where clinically appropriate. Finally, foster cross-functional collaboration between R&D, regulatory, manufacturing, and commercial teams to ensure launch readiness is synchronized with supply capacity, clinician training, and payer engagement plans. Executing these priorities will improve the likelihood of sustained access and meaningful patient benefit.

A robust mixed-method research methodology combining stakeholder interviews, secondary evidence synthesis, triangulation, and validation to ensure credible and actionable insights

This research employed a mixed-methods approach to generate rigorous, actionable insights that combine qualitative stakeholder perspectives with structured evidence synthesis. Primary research comprised in-depth interviews with clinical investigators, health system leaders, regulatory affairs specialists, payer representatives, and manufacturing experts, capturing firsthand perspectives on clinical endpoints, trial feasibility, reimbursement considerations, and supply chain constraints. Complementing these interviews, secondary evidence synthesis reviewed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map scientific progress, safety considerations, and regulatory posture.

Data triangulation validated thematic findings across sources and supported scenario analysis on supply chain and market access sensitivities. Segmentation mapping linked clinical development strategies to likely commercialization pathways, while thematic coding of qualitative interviews identified persistent barriers and successful mitigation strategies. The methodology incorporated stakeholder validation sessions to refine conclusions and ensure practical relevance for decision-makers. Limitations include the evolving regulatory environment and rapid scientific progress that may introduce new evidence after data collection; to mitigate this, the research applied conservative interpretation of emergent data and highlighted areas for ongoing monitoring. Ethical standards and confidentiality protocols governed all primary interactions and data handling.

Concluding synthesis underscoring momentum, multifaceted challenges, and strategic priorities required to translate anti-amyloid innovation into sustained patient access

In synthesis, the anti-amyloid therapy landscape presents a rare conjunction of scientific promise and systemic complexity that requires integrated, evidence-driven strategies. Therapeutic innovation across monoclonal antibodies, peptides, and small molecules offers diversified pathways to affect disease biology, yet each approach carries distinct manufacturing, clinical, and reimbursement challenges. Regulatory and payer environments are evolving in parallel, increasingly demanding real-world evidence and demonstrable functional outcomes, which necessitates proactive planning for post-approval studies and creative contracting models.

Stakeholders that succeed will be those that anticipate intersectional risks-manufacturing constraints, tariff impacts, diagnostic bottlenecks, and heterogeneous regional requirements-and that translate those anticipations into operational actions. Strategic alignment across development, manufacturing, diagnostics, and market access functions will reduce time-to-uptake and enhance patient reach. Ultimately, the field's momentum can translate into meaningful patient benefit if organizations commit to cross-disciplinary collaboration, adaptive evidence generation, and resilient commercialization execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-amyloid Therapy Market, by Therapy Type

  • 8.1. Monoclonal Antibodies
    • 8.1.1. Chimeric Monoclonal Antibodies
    • 8.1.2. Fully Human Monoclonal Antibodies
    • 8.1.3. Humanized Monoclonal Antibodies
  • 8.2. Peptides
  • 8.3. Small Molecules

9. Anti-amyloid Therapy Market, by Indication

  • 9.1. Alzheimer's Disease Mild-To-Moderate
    • 9.1.1. Mild Alzheimer's Disease
    • 9.1.2. Moderate Alzheimer's Disease
  • 9.2. Alzheimer's Disease Severe

10. Anti-amyloid Therapy Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Anti-amyloid Therapy Market, by Mechanism Of Action

  • 11.1. Beta Amyloid Aggregation Inhibition
  • 11.2. Beta Amyloid Clearance
  • 11.3. Beta Amyloid Production Reduction
  • 11.4. Neuroinflammation Modulation

12. Anti-amyloid Therapy Market, by Patient Age Group

  • 12.1. 65 To 74 Years
  • 12.2. 75 Years And Above
  • 12.3. Below 65 Years

13. Anti-amyloid Therapy Market, by End User

  • 13.1. Home Care
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals
  • 13.3. Specialty Clinics
  • 13.4. Telehealth Services

14. Anti-amyloid Therapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-amyloid Therapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-amyloid Therapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Anti-amyloid Therapy Market

18. China Anti-amyloid Therapy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Biogen Inc.
  • 19.9. Bristol Myers Squibb Company
  • 19.10. Eisai Co. Ltd.
  • 19.11. Eli Lilly and Company
  • 19.12. Gilead Sciences Inc.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Johnson & Johnson
  • 19.15. Merck & Co. Inc.
  • 19.16. Novartis AG
  • 19.17. Pfizer Inc.
  • 19.18. Roche Holding AG
  • 19.19. Sanofi S.A.
  • 19.20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-AMYLOID THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-AMYLOID THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY CHIMERIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY CHIMERIC MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY CHIMERIC MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY FULLY HUMAN MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY FULLY HUMAN MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY FULLY HUMAN MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HUMANIZED MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MILD ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MILD ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MILD ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID AGGREGATION INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID AGGREGATION INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID AGGREGATION INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID CLEARANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID CLEARANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID CLEARANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID PRODUCTION REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID PRODUCTION REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BETA AMYLOID PRODUCTION REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY NEUROINFLAMMATION MODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY NEUROINFLAMMATION MODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY NEUROINFLAMMATION MODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 65 TO 74 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 65 TO 74 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 65 TO 74 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 75 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 75 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY 75 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BELOW 65 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY BELOW 65 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY TELEHEALTH SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY TELEHEALTH SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY TELEHEALTH SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANTI-AMYLOID THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE MILD-TO-MODERATE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ANTI-AMYLOID THERAPY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)